

Telmisartan Decreases Microalbuminuria in Patients with Type 2 Diabetes Mellitus Following Coronary Artery Bypass Grafting.

Furat C, et al. Cardiovasc J Afr. 2016; 27:1-5.

- A prospective study investigated the effects of telmisartan on microalbuminuria after coronary artery bypass surgery (80 mg daily for at least 6 months in the pre-operative period) in patients with diabetes mellitus.
- Telmisartan decreased systemic inflammation and levels of urinary albumin excretion:
 - Microalbuminuria levels decreased significantly in the pre-operative period, first hour postoperatively and fifth day postoperatively.
 - C-reactive protein levels decreased significantly on the fifth day postoperatively.

Telmisartan was useful for decreasing systemic inflammation and urinary albumin excretion in patients who had type 2 diabetes mellitus and had undergone coronary artery bypass surgery.